Peptide-based bio company Caregen (CEO Yongji Jeong) announced that it participated in the pharmaceutical and bio exhibition 'CPHI South East AISA 2025' held in Kuala Lumpur, Malaysia from July 16th to 18th, and completed its schedule by showcasing its peptide platform technology and innovative major product groups.
At this exhibition, Caregen set up a large booth in the core area of the exhibition hall and unveiled a new slogan, “We Don't Just Add Years, We Redesign Longevity.” This slogan contains Caregen's philosophy and technological vision to redesign and realize 'healthy longevity' in the true sense of the word, which goes beyond simple life extension and scientifically improves the quality and function of life. Based on its peptide platform technology, Caregen emphasized that it is a leading company in the 'bio healthcare paradigm' that scientifically designs and optimizes an individual's entire lifelong health, beyond simple functionality improvement.
During this event, 110 companies from 20 countries visited the Caregen booth, and in particular, major Asian pharmaceutical companies from India, Bangladesh, Indonesia, Malaysia, and Thailand visited one after another, showing great interest in the three health functional foods developed by Caregen, Korglutide, Myoki, and ProGsterol, and discussing the possibility of cooperation.
Caregen’s booth visualized key information such as the mechanism of action, clinical results, and technology expandability of peptides to help visitors understand, and focused on intuitively conveying complex science and technology. Rather than simply listing information, it focused visitors’ attention by allowing them to experience how peptides work in the human body and what effects they have. Based on the peptide technology and excellence accumulated through 24 years of consistent research, Caregen actively held business meetings with various global companies during the exhibition period.
The product that attracted the most attention during the CPHI event was the oral GLP-1 peptide health functional food, ‘Korglutide.’ The CPHI organizers introduced the Caregen booth on the front page of the event’s official newsletter.
GLP-1-based products are currently attracting attention worldwide as a key trend in obesity treatment and glucose metabolism control, and coglutide is being developed as a health functional food that can be safely consumed by anyone and is being evaluated as a 'game changer' in the market.
Through this exhibition, Caregen has once again confirmed the global demand and scalability of peptide technology, and it is expected that this will lead to various partnerships and export contracts in the future.
“Just three years ago, when Caregen first launched ‘Progsterol,’ a health functional food based on synthetic peptides, awareness of oral peptides was low, but now the market atmosphere has completely changed,” said Caregen CEO Jeong Yong-ji. “Now, major companies from each country are approaching us first to request consultations.” He continued, “Recently, we have felt a clear difference in interest in and demand for Caregen’s peptide technology on global stages such as BIO USA and CPHI China.” He added, “There are many peptide pipelines in preparation that have not been disclosed yet, and we plan to disclose them sequentially after completing preclinical trials.”
- See more related articles
You must be logged in to post a comment.